Frank Pallone (Kevin Dietsch/Pool via AP Images)

House com­mit­tee seeks more from FDA on in­spec­tion back­log, when to restart work on for­eign sites

House En­er­gy & Com­merce com­mit­tee lead­ers are rais­ing fresh ques­tions about the FDA’s abil­i­ty to con­duct for­eign man­u­fac­tur­ing site in­spec­tions and bring down its grow­ing back­log.

“While we un­der­stand that the emer­gence of COVID-19 re­quired the agency to sus­pend in-per­son in­spec­tion ac­tiv­i­ties tem­porar­i­ly, we re­main con­cerned that more than one year in­to the pan­dem­ic, the strat­e­gy for re­sum­ing all in­spec­tions and ad­dress­ing the back­log of de­layed in­spec­tions re­mains un­clear,” E&C chair Frank Pal­lone (D-NJ) and a group of five oth­er bi­par­ti­san lead­ers of the com­mit­tee wrote to FDA act­ing com­mis­sion­er Janet Wood­cock.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA